A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Cancer Cell

Volumn 5, Issue 6, 2004, Pages 607-616

  Ma, Xiao Jun ^a   Wang, Zuncai ^b   Ryan, Paula D ^c   Isakoff, Steven J ^c,d   Barmettler, Anne ^b   Fuller, Andrew ^b   Muir, Beth ^b   Mohapatra, Gayatry ^b   Salunga, Ranelle ^a   Tuggle, J Todd ^a   Tran, Yen ^a   Tran, Diem ^a   Tassin, Ana ^a   Amon, Paul ^a   Wang, Wilson ^a   Wang, Wei ^a   Enright, Edward ^a   Stecker, Kimberly ^a   Estepa Sabal, Eden ^a   Smith, Barbara ^c   Younger, Jerry ^c   Balis, Ulysses ^b   Michaelson, James ^b   Bhan, Atul ^b   Habin, Karleen ^c   Baer, Thomas M ^a   Brugge, Joan ^c   Haber, Daniel A ^c   Erlander, Mark G ^a   Sgroi, Dennis C ^b   more..

^a Arcturus Bioscience Inc ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 2942578063     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.05.015     Document Type: Article

References (55)

1. Abate-Shen C. Deregulated homeobox gene expression in cancer. cause or consequence? Nat. Rev. Cancer. 2:2002;777-785
2. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:1987;3239-3245
3. Atalay G., Cardoso F., Awada A., Piccart M.J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 14:2003;1346-1363
4. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21:2003;1973-1979
5. Bonner R.F., Emmert-Buck M., Cole K., Pohida T., Chuaqui R., Goldstein S., Liotta L.A. Laser capture microdissection. Molecular analysis of tissue Science. 278:1997;1481-1483
6. Buzdar A.U. Anastrozole. a new addition to the armamentarium against advanced breast cancer Am. J. Clin. Oncol. 21:1998;161-166
7. Cantile M., Pettinato G., Procino A., Feliciello I., Cindolo L., Cillo C. In vivo expression of the whole HOX gene network in human breast cancer. Eur. J. Cancer. 39:2003;257-264
8. Chakravarti D., LaMorte V.J., Nelson M.C., Nakajima T., Schulman I.G., Juguilon H., Montminy M., Evans R.M. Role of CBP/P300 in nuclear receptor signalling. Nature. 383:1996;99-103
9. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 22:2003;7316-7339
10. Colleoni M., Curigliano G., Minchella I., Peruzzotti G., Nole F., Mazzarol G., Renne G., Orlando L., Rocca A., Veronesi P., et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction. cytotoxic treatment during the surgical phase Ann. Oncol. 14:2003;1477-1483. a
11. Colleoni M., Zarieh D., Gelber R.D., Viale G., Luini A., Veronesi P., Intra M., Galimberti V., Renne G., Goldhirsch A. Preoperative systemic treatment. prediction of responsiveness Breast. 12:2003;538-542. b
12. Dalton L.W., Pinder S.E., Elston C.E., Ellis I.O., Page D.L., Dupont W.D., Blamey R.W. Histologic grading of breast cancer. linkage of patient outcome with level of pathologist agreement Mod. Pathol. 13:2000;730-735
13. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 30:2003;256-268
14. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves. a nonparametric approach Biometrics. 44:1988;837-845
15. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer. 8:2001;191-195
16. EBCTCG Tamoxifen for early breast cancer. Cochrane Database Syst. Rev. 1:2001;CD000486
17. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer. evidence from a phase III randomized trial J. Clin. Oncol. 19:2001;3808-3816
18. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., Weiss R.A., Liotta L.A. Laser capture microdissection. Science. 274:1996;998-1001
19. Fernandez M.D., Alaghband-Zadeh J., Burn J.I. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy. Clin. Oncol. 9:1983;245-250
20. Ferno M., Stal O., Baldetorp B., Hatschek T., Kallstrom A.C., Malmstrom P., Nordenskjold B., Ryden S. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res. Treat. 59:2000;69-76
21. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124:2000;966-978
22. Gelmini S., Orlando C., Sestini R., Vona G., Pinzani P., Ruocco L., Pazzagli M. Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification. Clin. Chem. 43:1997;752-758
23. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349:2003;1793-1802
24. Gruvberger S.K., Ringner M., Eden P., Borg A., Ferno M., Peterson C., Meltzer P.S. Expression profiling to predict outcome in breast cancer. the influence of sample selection Breast Cancer Res. 5:2003;23-26
25. Hanstein B., Eckner R., DiRenzo J., Halachmi S., Liu H., Searcy B., Kurokawa R., Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA. 93:1996;11540-11545
26. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17:1999;1474-1481
27. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., Meltzer P., Gusterson B., Esteller M., Kallioniemi O.P., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344:2001;539-548
28. Huang E., Cheng S.H., Dressman H., Pittman J., Tsou M.H., Horng C.F., Bild A., Iversen E.S., Liao M., Chen C.M., et al. Gene expression predictors of breast cancer outcomes. Lancet. 361:2003;1590-1596
29. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J. Clin. Oncol. 17:1999;1974-1982
30. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther. 24:2002;A3-A16
31. Lichtner R.B. Estrogen/EGF receptor interactions in breast cancer. rationale for new therapeutic combination strategies Biomed. Pharmacother. 57:2003;447-451
32. Long A.A., Mueller J., Andre-Schwartz J., Barrett K.J., Schwartz R., Wolfe H. High-specificity in-situ hybridization. Methods and application. Diagn. Mol. Pathol. 1:1992;45-57
33. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., Payette T., Pistone M., Stecker K., Zhang B.M., et al. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA. 100:2003;5974-5979
34. Maulbecker C.C., Gruss P. The oncogenic potential of deregulated homeobox genes. Cell Growth Differ. 4:1993;431-441
35. Miller G.J., Miller H.L., van Bokhoven A., Lambert J.R., Werahera P.N., Schirripa O., Lucia M.S., Nordeen S.K. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 63:2003;5879-5888
36. Morgenstern J.P., Land H. Advanced mammalian gene transfer. high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line Nucleic Acids Res. 18:1990;3587-3596
37. Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res. Treat. 75(Suppl. 1):2002;S51-S55
38. Nardelli G.B., Lamaina V., Siliotti F. Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report). Eur. J. Gynaecol. Oncol. 7:1986;151-158
39. Nicholson R.I., McClelland R.A., Gee J.M., Manning D.L., Cannon P., Robertson J.F., Ellis I.O., Blamey R.W. Epidermal growth factor receptor expression in breast cancer. association with response to endocrine therapy Breast Cancer Res. Treat. 29:1994;117-125
40. Nicholson R.I., Gee J.M., Knowlden J., McClelland R., Madden T.A., Barrow D., Hutcheson I. The biology of antihormone failure in breast cancer. Breast Cancer Res. Treat. 80(Suppl 1):2003;S29-S34
41. Ory D.S., Neugeboren B.A., Mulligan R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA. 93:1996;11400-11406
42. Osborne C.K., Yochmowitz M.G., Knight W.A. 3rd, McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 46:1980;2884-2888
43. Osborne C.K., Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 12:2003;362-367
44. Pepe M.S. An interpretation for the ROC curve and inference using GLM procedures. Biometrics. 56:2000;352-359
45. Repesh L.A. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis. 9:1989;192-208
46. Shen W.F., Krishnan K., Lawrence H.J., Largman C. The HOX homeodomain proteins block CBP histone acetyltransferase activity. Mol. Cell. Biol. 21:2001;7509-7522
47. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., Borgen P.I., Clark G., Edge S.B., Hayes D.F., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20:2002;3628-3636
48. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98:2001;10869-10874
49. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 100:2003;8418-8423
50. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA. 100:2003;10393-10398
51. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D. Jr., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:1990;6075-6086
52. van de Vijver M.J., He Y.D., van 't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:2002;1999-2009
53. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
54. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., Speed T.P. Normalization for cDNA microarray data. a robust composite method addressing single and multiple slide systematic variation Nucleic Acids Res. 30:2002;e15
55. Zeltser L., Desplan C., Heintz N. Hoxb-13. a new Hox gene in a distant region of the HOXB cluster maintains colinearity Development. 122:1996;2475-2484